# Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations

> **NCT06229340** · PHASE2 · RECRUITING · sponsor: **N.N. Petrov National Medical Research Center of Oncology** · enrollment: 20 (estimated)

## Conditions studied

- RAS Mutation
- Ras (Kras or Nras) Gene Mutation
- Colorectal Cancer Recurrent
- Pancreas Cancer
- Lung Cancer
- Melanoma
- Refractory Cancer

## Interventions

- **DRUG:** Leflunomide
- **DRUG:** The combination of MEK inhibitor + hydroxychloroquine( plaquenil) ± bevacizumab

## Key facts

- **NCT ID:** NCT06229340
- **Lead sponsor:** N.N. Petrov National Medical Research Center of Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-03
- **Primary completion:** 2026-10-01
- **Final completion:** 2026-10-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06229340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06229340, "Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06229340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*